Oncodrex is a Canadian oncology company with a focus on triple negative breast cancer (TNBC). The company has identified unique molecular signatures in metastatic TNBC and is developing small molecules as drug candidates against this signature. This unique molecular signature also has allowed the company to develop a companion diagnostic to select responders to its TNBC drug candidate.
OncoDrex is also in clinical stage development of two other assets, a predicative diagnostic for hormone reception positive (HR+) breast cancer and a screening test for pre-cancerous polyps and colorectal cancer (CRC). The company intends to continue development of these assets to their next key inflection points.